Lehtonen A, Viikari J
Atherosclerosis. 1979 May;33(1):49-58. doi: 10.1016/0021-9150(79)90197-7.
Thirty hyperlipidaemic patients (19 with type IIA, 4 with IIB and 7 with type IV hyperlipoproteinaemia) were subjected to therapy with calcium clofibrate and calcium carbonate (4C, 2 + 2 g/day for 6 months) and the effect was compared with clofibrate (1C, 2 g/day) which was given for 6 months as well, in a single-blind placebo-controlled study. 4C and 1C decreased total serum cholesterol levels especially in subgroups IIA and IIB. 4C was somewhat more effective than 1C in decreasing (VLDL + LDL)-cholesterol in subgroup IIA. The HDL-cholesterol concentrations and the ratio of HDL-cholesterol and total cholesterol increased during treatment with both 1C and 4C. The HDL-cholesterol increase (vs. placebo) was 18%. The concentrations of serum triglycerides decreased by 33% during both treatment periods and there was no significant difference between 1C and 4C.
在一项单盲安慰剂对照研究中,30名高脂血症患者(19名IIA型、4名IIB型和7名IV型高脂蛋白血症患者)接受了安妥明钙和碳酸钙治疗(4C,2 + 2克/天,共6个月),并将其效果与同样服用6个月的安妥明(1C,2克/天)进行比较。4C和1C均可降低血清总胆固醇水平,尤其是在IIA和IIB亚组中。在IIA亚组中,4C在降低(极低密度脂蛋白+低密度脂蛋白)胆固醇方面比1C稍有效。在1C和4C治疗期间,高密度脂蛋白胆固醇浓度以及高密度脂蛋白胆固醇与总胆固醇的比率均升高。高密度脂蛋白胆固醇升高(与安慰剂相比)为18%。在两个治疗期内,血清甘油三酯浓度均下降了33%,1C和4C之间无显著差异。